{"organizations": [], "uuid": "f14071a449e918d923e0ecf784a87fedf3d62feb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-clovis-oncology-says-rubraca-appro/brief-clovis-oncology-says-rubraca-approved-in-u-s-as-maintenance-treatment-of-recurrent-ovarian-cancer-idUSFWN1RJ0DE", "country": "US", "domain_rank": 408, "title": "BRIEF-Clovis Oncology Says Rubraca Approved In U.S. As Maintenance Treatment Of Recurrent Ovarian Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-06T20:55:00.000+03:00", "replies_count": 0, "uuid": "f14071a449e918d923e0ecf784a87fedf3d62feb"}, "author": "", "url": "https://www.reuters.com/article/brief-clovis-oncology-says-rubraca-appro/brief-clovis-oncology-says-rubraca-approved-in-u-s-as-maintenance-treatment-of-recurrent-ovarian-cancer-idUSFWN1RJ0DE", "ord_in_thread": 0, "title": "BRIEF-Clovis Oncology Says Rubraca Approved In U.S. As Maintenance Treatment Of Recurrent Ovarian Cancer", "locations": [], "entities": {"persons": [{"name": "rubraca", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "u.s", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "clovis oncology inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 6 (Reuters) - Clovis Oncology Inc:\n* RUBRACA (RUCAPARIB) APPROVED IN THE U.S. AS MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER\n* U.S. FDA APPROVED RUBRACA TABLETS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CERTAIN TYPES OF RECURRENT CANCER\n* IN ADDITION TO GRANTING RUBRACA APPROVAL FDA CONVERTED APPROVAL OF INITIAL TREATMENT INDICATION FROM ACCELERATED TO REGULAR APPROVAL Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-06T20:55:00.000+03:00", "crawled": "2018-04-06T21:24:30.046+03:00", "highlightTitle": ""}